Download PDF
Zeitschrift für Phytotherapie 2017; 38(01): 27-31
DOI: 10.1055/s-0042-119173
Forschung
© Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Die Möglichkeiten eines supportiven Einsatzes der Phytotherapie bei Brustkrebspatientinnen[*]

Susanne Büttner
Further Information

Publication History

Publication Date:
09 May 2017 (online)

    Permissions and Reprints

Zusammenfassung

Chemo- und Hormontherapie des Mammakarzinoms gehen häufig mit unerwünschten Wirkungen einher, die für die betroffenen Patientinnen derart belastend sein können, dass ein Fortsetzen der geplanten Therapie bisweilen unmöglich ist. Ziel dieser Arbeit ist es, anhand einer Literaturrecherche am Beispiel der 3 hierzu am besten untersuchten Pflanzen Gelbwurz (Curcuma longa), Mariendistel (Silybum marianum) und Traubensilberkerze (Cimicifuga racemosa) eine mögliche Bedeutsamkeit der Phytotherapie in der supportiven Behandlung v. a. durch Linderung dieser Beschwerden zu untersuchen. Im Vordergrund stehen die Ergebnisse klinischer Studien. Studien zur Misteltherapie in vergleichbaren klinischen Situationen wurden dabei wegen leicht erreichbarer Übersichtsarbeiten bewusst nicht bearbeitet.

Für alle 3 untersuchten Pflanzen fanden sich in den wenigen publizierten klinischen Studien positive Trends, die eine supportive Anwendung bei Brustkrebspatientinnen unter Chemo- und Hormontherapie nahelegen. Es wäre wünschenswert, wenn dieser Trend sich durch weitere qualitativ hochwertige Studien bestätigen ließe.

Summary

The potential role of phytotherapy as a supportive treatment in breast cancer patients Chemotherapy and endocrine therapy of breast cancer are often accompanied by undesirable side effects, which can be so debilitating for the patient, that continuation of the treatment might not be possible. Based on a literature review of clinical trials on three plants, turmeric (Curcuma longa), milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa), the objective of this article is to investigate a potential role of phytotherapy as a supportive treatment of some of the side effects encountered by breast cancer patients undergoing chemo- or endocrine therapy. This article deliberately did not include studies on mistletoe therapy in comparable clinical situations due to the ready availability of a wide range of appropriate reviews.

The few published clinical trials on all three plants show a positive trend with regards to their potential as a supportive treatment of breast cancer patients. However, more high-quality trials are required to corroborate the findings in this review.

Schlüsselwörter

Phytotherapie - Brustkrebs - unerwünschte Wirkungen - Curcuma longa - Silybum marianum - Cimicifuga racemosa

Key words

phytotherapy - breast cancer - side effects - Curcuma longa - Silybum marianum - Cimicifuga racemosa

* Die hier veröffentliche Arbeit ist eine Abschluss­arbeit aus der Fortbildungsreihe „Phytotherapie für Ärzte“ in der Klinik Blankenstein, Hattingen 2014–2016. Prof. Dr. med. André-Michael Beer begleitete fachlich die Manuskriptentstehung.


 

  • Literatur

  • 1 Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009; 30: 85-94
    CrossrefPubMedGoogle Scholar
  • 2 Beer AM. Neff A. Differentiated evaluation of extract-specific evidence on Cimicifuga race­mosa’s efficacy and safety for climacteric complaints. Evid Based Complement Alternat Med 2013; 2013: 860602
    PubMedGoogle Scholar
  • 3 Belcaro G, Hosoi M, Pellegrini L. et al. A controlled study of a lecithinized delivery system of curcumin (Meriva®) to alleviate the adverse effects of cancer treatment. Phytother Res 2014; 28: 444-450
    CrossrefPubMedGoogle Scholar
  • 4 Bodinet C, Freudenstein J. Influence of Cimicifuga racemosa on the proliferation of estrogen receptor-positive human breast cancer cells. Breast Cancer Res Treat 2002; 76: 1-10
    PubMedGoogle Scholar
  • 5 Boh M, Breakspear I. Herbal Monograph: Silybum marianum – ancient medicine for modern times. http://www.anpa.asn.au (Accessed: 14 April 2015)
    PubMed
  • 6 Comelli MC, Mengs U, Schneider C, Prosdocimi M. Toward the definition of the mechanism of action of Sylimarin: activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther 2007; 6: 120-129
    CrossrefPubMedGoogle Scholar
  • 7 Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 2004; 3: 294-300
    CrossrefPubMedGoogle Scholar
  • 8 Enjalbert F, Rapior S, Nougier-Soulé J. et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol 2002; 40: 715-757
    CrossrefPubMedGoogle Scholar
  • 9 Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 2009; 6: 928-939
    CrossrefPubMedGoogle Scholar
  • 10 Goel A, Aggarwal BB.. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010; 62: 919-930
    CrossrefPubMedGoogle Scholar
  • 11 Green J, Kalisch A, the CAM-Cancer Consortium. Milk thistle (Silybum marianum). http://www.cam-cancer.org/CAM-Summaries/ Herbal-products/Milk-thistle-Silybum-marianum; 2013 (Accessed: 14 April 2015)
    PubMed
  • 12 Greenlee H, Abascal K, Yarnell E, Ladas E. Clinical applications of Silybum marianum in oncology. Integr Cancer Ther 2007; 6: 158-165
    CrossrefPubMedGoogle Scholar
  • 13 Henneicke-von Zepelin HH, Meden H, Kostev K. et al. Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. Int J. Clin Pharmacol Ther 2007; 45: 143-154
    CrossrefPubMedGoogle Scholar
  • 14 Invernizzi R, Bernuzzi S, Ciani D, Ascari E. Silymarine during maintenance therapy of acute promyelocytic leukemia. Haematologica 1993; 78: 340-341
    PubMedGoogle Scholar
  • 15 Jacobson JS, Troxel AB, Evans J. et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001; 19: 2739-2745
    CrossrefPubMedGoogle Scholar
  • 16 Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: A review of preclinical and clinical research. Altern Med Rev 2009; 14: 141-153
    PubMedGoogle Scholar
  • 17 Ladas EJ, Kelly KM. Milk thistle: Is there a role for its use as an adjunct therapy in patients with cancer?. J Altern Complement Med 2003; 9: 411-416
    CrossrefPubMedGoogle Scholar
  • 18 Ladas EJ, Kroll DJ, Oberlies NH. et al. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer 2010; 116: 506-513
    CrossrefPubMedGoogle Scholar
  • 19 McBride A, Augustin KM, Nobbe J, Westervelt P. Silybum marianum (milk thistle) in the management and prevention of hepatotoxicity in a patient undergoing reinduction therapy for acute myelogenous leukemia. J Oncol Pharm Practice 2012; 18: 360-365
    CrossrefPubMedGoogle Scholar
  • 20 Muñoz GH, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas 2003; 44 (Suppl. 01) S59-S65
    CrossrefPubMedGoogle Scholar
  • 21 Naser B, Schnitker J, Minkin MJ. et al. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled trials for isopropanolic black cohosh extract. Menopause 2011; 18: 366-375
    CrossrefPubMedGoogle Scholar
  • 22 Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res 2014; 28: 1461-1467
    CrossrefPubMedGoogle Scholar
  • 23 Pockaj B, Loprinzi MD, Sloan JA. et al. Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Invest 2004; 22: 515-521
    CrossrefPubMedGoogle Scholar
  • 24 Pockaj BA, Gallagher JG, Loprinzi CL. et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG trial No1CC. J Clin Oncol 2006; 24: 2836-2841
    CrossrefPubMedGoogle Scholar
  • 25 Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). ­Integr Cancer Ther 2007; 6: 104-109
    PubMedGoogle Scholar
  • 26 Rostock M, Fischer J, Mumm A. et al. Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints – a prospective observational study. Gynecol Endocrinol 2011; 27: 844-848
    CrossrefPubMedGoogle Scholar
  • 27 Ruhlen RL, Haubner J, Tracy JK. et al. Black ­cohosh does not exert estrogenic effect on the breast. Nutr Cancer 2007; 59: 269-277
    CrossrefPubMedGoogle Scholar
  • 28 Scambia G, De Vincenzo R, Ranelletti FO. et al. Antiproliferative effect of Silybin on gynaecological malignancies: synergism with Cisplatin and Doxorubicin. Eur J Cancer 1996; 32A: 877-882
    PubMedGoogle Scholar
  • 29 Shanmugam MK, Kannaiyan R, Sethi G. Targeting cell signalling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer. Nutr Cancer 2011; 63: 161-173
    CrossrefPubMedGoogle Scholar
  • 30 Sharma RA, Gescher AJ, Steward WP. Curcu­min: The story so far. Eur J Cancer 2005; 41: 1955-1968
    CrossrefPubMedGoogle Scholar
  • 31 Sheu T, Jhan H, Hsieh C. et al. Efficacy of antioxidants as a complementary and alternative medicine (CAM) in combination with the ­chemotherapeutic agent doxorubicin. Integr Cancer Ther 2015; 14: 184-195
    CrossrefPubMedGoogle Scholar
  • 32 Siviero A, Gallo E, Maggini V. et al. Curcumin, a golden spice with low bioavailability. J Herbal Med 2015; 5: 57-70
    PubMedGoogle Scholar
  • 33 Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm: a critical review. Menopause 2010; 17: 426-440
    CrossrefPubMedGoogle Scholar
  • 34 Tyagi AK, Agarwal C, Chan DC, Agarwal R. ­Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, ­cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB48 cells. ­Oncology Reports 2004; 11: 493-499
    PubMedGoogle Scholar
  • 35 Wuttke W, Jarry H, Becker T. et al. Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy?. Maturitas 2003; 44 (Suppl. 01) S9-S20
    CrossrefPubMedGoogle Scholar